Further positive note to look forward in 2023.
United States The Group is on track to meet all regulatory milestones for permanent access to the U.S. market and is working closely with the FDA and other stakeholders to help diversify America’s infant formula supply chain and secure ongoing availability in the American market.
The Group has received confirmation that SAMR has formally accepted lodgement of Heilongjiang’s application. Subject to SAMR approval being granted in 2023, the renewed licence will enable Bubs® Goat Infant Formula China-label products to be sold into the General Trade throughout China.
Ann: Bubs Australia - Half Year Results Presentation, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $156.2M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 17.0¢ | $205.8K | 1.176M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 1379277 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1105948 | 23 |
View Market Depth
| Last trade - 16.10pm 23/07/2025 (20 minute delay) ? |
| BUB (ASX) Chart |